Drug-resistant tuberculosis (TB) remains a major challenge for global TB control. Resistance can arise from MDR/XDR strains or factors like delayed diagnosis and inadequate treatment. Timely detection is critical, yet traditional drug susceptibility testing (DST) using culture methods takes weeks due to the slow growth of Mycobacterium tuberculosis, increasing the risk of MDR and XDR-TB spread. While rapid molecular tests exist, their high-cost limits accessibility in resource poor regions.
Genes2Me’s NGS-based TB panel offers a breakthrough delivering fast, accurate detection for Mycobacterium Tuberculosis Complex and drug-resistant TB enabling early intervention, optimized therapy, and improved patient outcomes. Using high throughput targeted sequencing approach directly from clinical specimens and eliminating the need for culture, this assay is designed to map 100 kb region of the M. tuberculosis genome for 75 genes and associated mutation sites, as well as SNP loci. Get a complete drug-resistance profile for all major first and second line anti-TB drugs (including drug resistance, MDR, Pre-XDR, and XDR) with the Genes2Me TB NGS Assay. Powered by advanced hybridization capture-based target enrichment, this assay delivers high-accuracy detection of resistance mutations, enabling rapid, comprehensive insights for effective treatment planning.
Drug Resistance Profiling: With the G2M TB NGS Assay, unlock a complete drug-resistance profile for all major first and second line anti-TB drugs. This advanced panel also includes coverage for the latest WHO approved nitroimidazole antibiotics Delamanid and Pretomanid used in BPaL and BPaLM treatment regimens. The table lists major anti-TB drugs grouped by treatment lines and WHO recommended categories:
| First Line | Rifampicin | |
| Isoniazid | ||
| Ethambutol | ||
| Pyrazinamide | ||
| Second Line | Group A | Bedaquiline |
| Linezolid | ||
| Moxifloxacin | ||
| Levofloxacin | ||
| Group B | Clofazimine | |
| Cycloserine | ||
| Group C | Delamanid | |
| Ethionamide | ||
| Amikacin | ||
| Streptomycin | ||
| Para-aminosalicylic acid | ||
| Others | Pretomanid | |
| Capreomycin | ||
| Kanamycin |
Detects mutations for all major first and second line anti TB drugs, including MDR, Pre-XDR, and XDR strains.
Accurately identifies Mycobacterium tuberculosis and differentiates species for precise diagnosis.
Determines TB lineage to support epidemiological studies and guide treatment strategies.
Provides rapid results without lengthy culture-based drug susceptibility testing, reducing turnaround time from weeks to days.
Uses hybridization capture-based target enrichment for high resolution sequencing of resistance associated genes.
Enables tailored treatment plans, early detection, and informed strategies to combat drug resistant TB.
| Panel name: | Med4Me Tuberculosis Panel |
| Target region: | 100 Kb |
| Methodology: | Hybridization capture-based target enrichment |
| Input Sample type: | gDNA from clinical samples (sputum / culture / BAL) |
| DNA input quantity: | 50 - 100 ng |
| Recommended sequencers: | Illumina, MGI, Element Biosciences (AVITI) |
Comprehensive Mapping of TB Resistance Genes to Antibiotics:
The chord diagram visualizes connections between Mycobacterium tuberculosis resistance genes and anti-TB drugs, including first line, second line, and WHO-approved regimens. This mapping highlights critical genetic determinants of MDR, Pre-XDR, and XDR-TB, enabling rapid detection and guiding precision treatment strategies by the G2M panel.
Uniform Coverage for Key Drug-Resistance Genes:
The plot illustrates gene wise coverage and average sequencing depth across 32 TB samples for critical resistance-associated genes (inhA, rpoB, katG, fabG1, pncA, gid). Coverage remains consistently high across all targets, while average depth (blue line) demonstrates robust sequencing performance. Accurate detection of resistance mutations ensures uniformity supporting reliable diagnosis and tailored therapeutic planning for MDR, Pre-XDR, and XDR-TB.
Distribution of Resistance Among First and Second Line TB Drugs:
he graph illustrates the relative abundance of drug resistance across first-line and second-line anti-TB medications. Higher resistance is observed for primary drugs such as Isoniazid, Rifampicin, Pyrazinamide, and Ethambutol, followed by Fluoroquinolones. Second-line drugs including Amikacin, Kanamycin, Capreomycin, Streptomycin, Ethionamide, Bedaquiline, Clofazimine, and Linezolid show variable resistance patterns. This highlights the importance of comprehensive resistance profiling for effective TB treatment planning.
Genetic Determinants of TB Drug Resistance Across Patient Samples:
The diagram illustrates the association between Mycobacterium tuberculosis resistance genes and corresponding anti-TB drugs. Each segment represents a drug class linked to specific mutations. This integrated view highlights the genetic basis of resistance across first-line, second-line, and newer WHO recommended drugs, supporting identification to guide targeted TB therapy.
| Commercial Name | Cat No. | Pack Size | Platform |
|---|---|---|---|
| TB NGS test Kit | G710010-1 | 24 T | Illumina |
| G710010-2 | 96 T | Illumina | |
| G710010-3 | 96 T - EZY | Illumina - EZY | |
| TB NGS test Kit | G710010-4 | 24 T | MGI |
| G710010-5 | 96 T | MGI | |
| G710010-6 | 96 T - EZY | MGI - EZY | |
| TB NGS test Kit | G710010-7 | 24 T | Aviti |
| G710010-8 | 96 T | Aviti | |
| G710010-9 | 96 T - EZY | Aviti - EZY | |
| TB NGS test Kit | G710010-10 | 24 T | Thermo |
| G710010-11 | 96 T | Thermo | |
| G710010-12 | 96 T - EZY | Thermo - EZY |
Download useful documents and technical information for the tbNGS Kit.
Since its inception in 2016, Genes2me has been constantly striving towards setting a benchmark in the diagnostics space by introducing premium quality (Made in India) diagnostic kits which are CE-IVD, ISO-13485:2016, and ISO 9001:2015 certified, assuring our clients of unparalleled quality and compliance with international standards.
All products listed in the catalogue are the products of Genes2Me Private Limited. Apart from that, all other product names, trademarks and logos wherever used in the catalogue are the property of their respective owners.
© 2025 Genes2me. All rights reserved.
